ReShape Lifesciences Inc
NASDAQ:RSLS
ReShape Lifesciences Inc
NASDAQ:RSLS
Price:
0.168 USD
0.18%
Market Closed
Updated:
May 13, 2024
ReShape Lifesciences Inc
Cost of Revenue
|
ReShape Lifesciences Inc
Cost of Revenue Peer Comparison
Comparables:
BDX
BSX
SYK
ABT
ISRG
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ReShape Lifesciences Inc
NASDAQ:RSLS
|
Cost of Revenue
-$3.1m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cost of Revenue
-$11.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-11%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$4.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$7.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$18B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$2.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-14%
|
See Also
What is ReShape Lifesciences Inc's Cost of Revenue?
Cost of Revenue
-3.1m
USD
-3.1m
USD
Based on the financial report for Dec 31, 2023, ReShape Lifesciences Inc's Cost of Revenue amounts to -3.1m USD.
What is ReShape Lifesciences Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
10%
10%
Over the last year, the Cost of Revenue growth was 30%. The average annual Cost of Revenue growth rates for ReShape Lifesciences Inc have been -46% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
